GlassScriptPhysician profile
Sarah Haseen
NPI 1407484033
$1,125.31
in general payments reported to CMS, 2019-2025
18 companies · $70.78 in 2025
The $70.78 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $69.76 · 2023: $677 · 2024: $307 · 2025: $70.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $185.74 | 2023-2024 | Briviact, Fintepla |
| Celgene Corporation | $175.54 | 2023-2024 | Zeposia |
| Csl Behring | $124.99 | 2023 | Hizentra |
| Neurelis, INC. | $122.65 | 2022-2024 | Valtoco |
| Abbvie INC. | $80.24 | 2022-2025 | |
| Argenx US, INC. | $71.33 | 2023 | Vyvgart, Vyvgart Hytrulo |
| Jazz Pharmaceuticals INC. | $58.24 | 2023 | Epidiolex |
| Genentech USA, INC. | $47.21 | 2024 | Ocrevus |
| Sk Life Science, INC. | $46.07 | 2023 | |
| Biogen, INC. | $38.71 | 2023-2025 | Vumerity, Spinraza |
| Alnylam Pharmaceuticals INC. | $34.46 | 2023 | Onpattro |
| Acadia Pharmaceuticals INC | $29.17 | 2023-2024 | Nuplazid |
| Biohaven Pharmaceutical Holding Company LTD. | $23.15 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.06 | 2023 | Gammagard |
| Lundbeck LLC | $19.52 | 2023 | Vyepti |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $18.78 | 2023 | Nourianz |
| Genzyme Corporation | $16.31 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.14 | 2024 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Haseen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.